Company reports record revenue of $1.7 million in Q3 Company announced a partnership in the high growth biopesticides sector that is expected to generate over $2 million in revenue in its first year Company closed a brokered financing for aggregate gross proceeds of $1.6 million Company signed a royalty agreement with Kalsec that includes milestone payments and tiered royalty payments on net worldwide sales after launch... Read More

SUNNYVALE, Calif. , Nov. 7, 2024 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable functional ingredients, announces that it has partnered a high value ingredient from its internal portfolio with a global ingredient manufacturer to fully develop, scale, and... Read More

Rapid success of first program leads to second collaboration to develop optimized enzyme for large scale manufacturing process Enzyme development expected to enable commercial-scale production of the API in 2025 SUNNYVALE, Calif. , Sept. 18, 2024 /CNW/ - Willow Biosciences Inc. ("Willow") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and... Read More

The agreement with Kalsec anticipates milestone payments for finalizing research and development work and a royalty stream for Willow upon commercialization SUNNYVALE, Calif. , Sept. 5, 2024 /CNW/ - Willow Biosciences Inc. (" Willow ") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable ingredients, announces signing a commercial... Read More

Company reports record revenue of $1.0 million , an increase of approximately 600% over the second quarter of 2023 Signed strategic partnership with leading pharmaceutical manufacturer, Laurus Labs, to develop biobased processes for seven high value APIs with large, existing markets Company now anticipates revenue of over $4 million in 2024 on existing programs SUNNYVALE, Calif. , Aug. 12, 2024 /CNW/ - Willow Biosciences... Read More

After a successful feasibility study, Company expands into the high growth biopesticide sector with a funded research and development program to produce valuable natural ingredients using its precision fermentation platform Program expected to generate over $2 million in revenue in first year with guaranteed payments of over $1 million in 2024 Company now anticipates revenue of over $4 million in 2024 on existing programs... Read More

SUNNYVALE, Calif. , July 26, 2024 /CNW/ - Willow Biosciences Inc. (" Willow " or the " Company ") (TSX: WLLW) (OTCQB: CANSF) is pleased to announce the voting results from its annual general and special meeting of shareholders held on July 26, 2024 (the " Meeting "). A total of 27,685,611 common shares, representing approximately 21.74% of the Company's issued and outstanding shares were represented at the meeting. The... Read More

CALGARY, AB , July 18, 2024 /CNW/ - Willow Biosciences Inc. (" Willow " or the " Company ") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable functional ingredients, is pleased to announce that it has closed its previously announced brokered private placement offering of 16,397,365 units (" Units ") of the Company at a price of... Read More

Company announced multi-product development and licensing partnership with Laurus Labs for manufacturing active pharmaceutical ingredients Company anticipates revenue of over $1.0 million in Q2, and over $3.5 million for 2024 on existing programs Company expands its AI platform with the appointment of AI expert and industry veteran Dr. Richard Fox as Senior Advisor, AI Platform Technologies Company appoints Mr. Gregory... Read More

SUNNYVALE, Calif. , June 3, 2024 /CNW/ - Willow Biosciences Inc. (" Willow " or the " Company ") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable ingredients, announces a brokered private placement offering (the " Offering ") of up to 30,000,000 units (" Units ") of Willow at an issue price of C$0.10 per Unit (the " Offering... Read More

Collaboration provides Laurus access to Willow's AI-driven bioengineering platform The strategic alliance includes an initial seven high-value advanced intermediates and active pharmaceutical ingredients, including Willow's corticosteroid programs The agreement with Laurus is the largest collaboration agreement Willow has signed to date SUNNYVALE, Calif. , May 30, 2024 /CNW/ - Willow Biosciences Inc. (" Willow ") (TSX: WLLW)... Read More

Company continues to advance its corticosteroid production platform and anticipates signing a large strategic partnership in Q2 2024 Signed two new program agreements, and advanced three programs to the next phase of development toward commercialization Willow reiterates its expectations of at least doubling its full year 2024 revenues SUNNYVALE, Calif. , May 13, 2024 /CNW/ - Willow Biosciences Inc. (" Willow " or the "... Read More

Completed the reorganization of the Company during 2023 with all lab operations now located in the Sunnyvale, California Record revenue in 2023 of $1.2 million representing 43% growth over 2022 Record number of new collaborations executed in 2023, with four new partnerships during the year that position Willow for continued growth in 2024 SUNNYVALE, Calif. , March 28, 2024 /CNW/ - Willow Biosciences Inc. ("Willow" or the... Read More

CALGARY, AB , Feb. 29, 2024 /CNW/ - Willow Biosciences Inc. (" Willow " or the " Company ") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable functional ingredients, is pleased to announce a second strategic investment (the " Milestone Investment "), by way of non-brokered private placement, from Kalsec ® Inc. (" Kalsec "), a... Read More

Investment further validates Willow's technology for the development and sustainable manufacture of natural ingredients Additional capital will accelerate commercialization of Willow's pipeline CALGARY, AB , Feb. 20, 2024 /CNW/ - Willow Biosciences Inc. (" Willow " or the " Company ") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and... Read More

SUNNYVALE, Calif. , Jan. 31, 2024 /CNW/ - Willow Biosciences Inc. (" Willow ") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable ingredients, today announced a collaboration with a leading Active Pharmaceutical Ingredient ("API") manufacturer to develop a more sustainable, cost-effective manufacturing route for their largest... Read More

SUNNYVALE, Calif. , Jan. 16, 2024 /CNW/ - Willow Biosciences Inc. (" Willow ") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable ingredients, today announced a collaboration with Enterin, Inc. (" Enterin "), a clinical stage biopharmaceutical company pioneering novel treatments that target neurodegenerative and metabolic... Read More

Estimated FY 2023 revenues in excess of $1.3 million is a record year for the Company Anticipate closing at least three new partnership development agreements including one for our corticosteroid API program, and one new commercial agreement under an existing partnership development program FY 2024 revenues are expected to increase by more than 100%, which would be another record year for Willow SUNNYVALE, Calif. , Jan. 10,... Read More

Program brings immediate R&D revenue and first commercial supply revenue as early as 2024 Program further validates Willow's BioOxi™ technology and focus on commercial execution and aligns with its strategic focus on near term revenue generation SUNNYVALE, Calif. , Dec. 7, 2023 /CNW/ - Willow Biosciences Inc. (" Willow ") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial... Read More

Record revenues for the third quarter and the nine months ended September 30, 2023 Patent application filed for a process to produce corticosteroids at an expected significant cost reduction to current manufacturing cost Signed two new program agreements, and advanced three programs to the next phase of development toward commercialization SUNNYVALE, Calif. , Nov. 14, 2023 /PRNewswire/ - Willow Biosciences Inc. (" Willow ")... Read More

CALGARY, AB , Oct. 10, 2023 /CNW/ - Willow Biosciences Inc. (" Willow " or the " Company ") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients, is pleased to announce the completion of its previously announced offering of convertible debenture units of the Company (the " Debenture Units "), on a... Read More

SUNNYVALE, Calif. , Oct. 3, 2023 /CNW/ - Willow Biosciences Inc. , ( "Willow" ) (TSX: WLLW) (OTCQB: CANSF) and SUANFARMA today jointly announced execution of a collaboration agreement for a cell line productivity optimization development program for manufacturing a large volume anti-infective Active Pharmaceutical Ingredient ("API") through precision fermentation. Through the partnership, SUANFARMA will have access to... Read More

CALGARY, AB , Sept. 12, 2023 /CNW/ - Willow Biosciences Inc. (" Willow " or the " Company ") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients, is pleased to announce an offering of convertible debenture units of the Company (the " Debenture Units "), on a non-brokered private placement basis, for... Read More

Company's BioOxi™ Platform solves for selective C-H hydroxylation, one of the "Holy Grails" of chemistry BioOxi is broadly applicable to manufacturing of intermediates and active pharmaceutical ingredients, particularly for steroid applications SUNNYVALE, Calif. , Sept. 6, 2023 /CNW/ - Willow Biosciences Inc. (" Willow ") (TSX: WLLW; OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial... Read More

Company's BioOxi™-based process reduces number of steps and associated costs of corticosteroids manufacturing by up to two-thirds SUNNYVALE, Calif. , Aug. 30, 2023 /CNW/ - Willow Biosciences Inc. (" Willow ") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable functional ingredients, announces the development of a process to... Read More

Announces commercial focus on BioOxi TM bio-oxidation platform as part of targeted alignment on nearer-term and larger revenue opportunities Reduces number of board members as part of geographic transition as a San Francisco Bay Area -based biotech company SUNNYVALE, Calif. , Aug. 24, 2023 /CNW/ - Willow Biosciences Inc. (" Willow ") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing... Read More

SUNNYVALE, Calif. , Aug. 21, 2023 /CNW/ - Willow Biosciences Inc. (" Willow ") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients, today announced a collaboration with a Nasdaq-listed biopharma company to develop new sustainable manufacturing routes to key intermediates and active pharmaceutical ingredients... Read More

New partnerships and contracts expected to bring in over $1 million in near-term R&D/milestone revenue and generate long term commercial revenue SUNNYVALE, Calif. , Aug. 8, 2023 /CNW/ - Willow Biosciences Inc. (" Willow ") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable functional ingredients, today released its financial and... Read More

President and CEO Dr. Chris Savile to provide business update at event open to all investors SUNNYVALE, Calif. , Aug. 2, 2023 /CNW/ - Willow Biosciences Inc. (" Willow ") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients announces that it will present at the upcoming Emerging Growth Conference August 8-9,... Read More

Program further validates Willow's technology and focus on commercial execution and aligns with its strategic focus on near term revenue generation KALAMAZOO, Mich. and SUNNYVALE, Calif. , July 20, 2023 /CNW/ - Willow Biosciences Inc. (" Willow ") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients, and... Read More

President and CEO Dr. Chris Savile to provide business update at event open to all investors MOUNTAIN VIEW, Calif. , June 7, 2023 /CNW/ - Willow Biosciences Inc. (" Willow ") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients announces that it has been invited to present at the Emerging Growth Conference on... Read More

Biotech partner recognizes strength of Willow's first in class FutureGrown ™ technology platform for producing natural products Further expansion and diversification of Willow's product portfolio with collaboration revenue expected in 2023 and potential for near-term commercial product revenue MOUNTAIN VIEW, Calif. , May 31, 2023 /CNW/ - Willow Biosciences Inc. (" Willow ") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology... Read More

Rapid success of first collaboration leads to partnership on high-value specialty ingredient Enzyme development expected to enable commercial-scale production in 2024 KALAMAZOO, Mich. and MOUNTAIN VIEW, Calif. , May 23, 2023 /CNW/ - Willow Biosciences Inc. (" Willow ") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional... Read More

MOUNTAIN VIEW, Calif. , May 12, 2023 /CNW/ - Willow Biosciences Inc. (" Willow " or the " Company ") (TSX: WLLW) (OTCQB: CANSF) is pleased to announce the voting results from its annual general and special meeting of shareholders held on May 12, 2023 (the " Meeting "). A total of 57,318,575 common shares, representing approximately 46.329% of the Company's issued and outstanding shares were represented at the meeting. The... Read More

Starts off year with significant commercial momentum toward focus on delivering robust year-over-year revenue growth for 2023 Previous steps taken to further optimize Willow's business, focus on near-term revenue generation and reduce cash burn are paying off MOUNTAIN VIEW, Calif. , May 11, 2023 /CNW/ - Willow Biosciences Inc. (" Willow " or the " Company ") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused... Read More

Commercial agreement follows the early success on the development phase of the UDCA program with Sandhill One Solid execution on development phases leads to execution of agreement; illustrates company progress against targeted milestones anticipated for 2023 to expand company growth Willow's unique combination of strain engineering, precision fermentation and its newly developed BioOxi™ bio-oxidation platform has accelerated... Read More

Complements Company's significant expertise in existing strain engineering and precision fermentation Offers commercial partners more rapid product innovation at significantly reduced cost by removing multiple chemical steps in producing oxygenated and hydroxylated functional ingredients Creates additional business development opportunities and enables faster path to nearer-term revenue for Willow relative to legacy strain... Read More

Willow Continues its Transition to the Bay Area in California with Management Promotions and a New Board Member MOUNTAIN VIEW , Calif. , March 28, 2023 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable ingredients, is pleased to announce that the Board of Directors has... Read More

CALGARY, AB and MOUNTAIN VIEW, Calif. , March 22, 2023 /CNW/ - WILLOW BIOSCIENCES , (TSX: WLLW) (OTCQB: CANSF) and SUANFARMA today jointly announced that they have, together with SUANFARMA's CIPAN manufacturing site, completed the development and manufacturing process in pilot scale for the WILLOW-owned ingredient, Cannabigerol (CBG). The 36 m 3 scaling-up production batches required for the forthcoming qualification and... Read More

Reports Highest Quarterly and Annual Revenue in Company History with Significant Year-Over-Year Growth Expected for 2023 CALGARY, AB and MOUNTAIN VIEW, Calif. , March 21, 2023 /CNW/ - Willow Biosciences Inc. ("Willow") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients is pleased to announce its financial... Read More

Dr. Lalonde has pioneered key advancements in enzyme engineering and biocatalysis that has revolutionized chemical production, protein engineering for food and nutrition, as well as drug discovery and development leading to new routes to pharmaceutical actives behind blockbuster drugs CALGARY, AB and MOUNTAIN VIEW, Calif. , Feb. 22, 2023 /CNW/ - Willow Biosciences Inc . (" Willow ") (TSX: WLLW) (OTCQB: CANSF), a leading... Read More

Represents early progress against targeted milestones anticipated for 2023 to expand company growth CALGARY , AB and MOUNTAIN VIEW, Calif , Jan. 17, 2023 /CNW/ - Willow Biosciences Inc. (" Willow ") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients announced today a follow-on engagement with Sandhill One,... Read More

CALGARY, AB AND MOUNTAIN VIEW, Calif. , Dec. 14, 2022 /CNW/ - Willow Biosciences Inc . (" Willow " or the " Company ") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients announced today a recap of key milestones the Company has successfully achieved in 2022, as well as its business outlook and key targeted... Read More

CALGARY, AB and MOUNTAIN VIEW, Calif , Dec. 7, 2022 /CNW/ - Willow Biosciences Inc. (" Willow ") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients announced today that it has taken additional steps to focus on near-term revenue generation, protect its balance sheet and reduce its cash burn. Since the early... Read More

KALAMAZOO, Mich. and CALGARY, AB and MOUNTAIN VIEW, Calif. , Nov. 8, 2022 /CNW/ - Willow Biosciences Inc . (" Willow ") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients and Kalsec® Inc. (" Kalsec " ), a leading global producer of natural taste and sensory, food protection, colors and advanced hops... Read More

Willow Biosciences Inc. (" Willow " or the " Company ") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable functional ingredients, today announced that it will host a webcast investor presentation on Thursday, November 10th at 2:00 PM EST . During the webcast, Dr. Peter Seufer-Wasserthal, Willow's President and Chief Executive... Read More

Willow Biosciences Inc. (" Willow " or the " Company ") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients, has released its financial and operating results for the three and nine months ended September 30, 2022 , reporting significant progress to its operational platform, leadership and strong liquidity.... Read More

Willow Biosciences Inc. (" Willow " or the " Company ") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients, is pleased to announce that it has completed proof of concept work, and has started yeast strain optimization and process development toward commercial production of astaxanthin, a powerful, naturally... Read More

Willow Biosciences Inc. (" Willow " or the " Company ") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients, is pleased to provide an update on cannabigerol (" CBG "), the Company's first commercialized functional ingredient in its portfolio. "As we expand our portfolio of products and partnerships, we also... Read More

Willow Biosciences Inc . (" Willow " or the " Company ") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients, has released its financial and operating results for the three months ended June 30, 2022 , reporting significant progress to its operational platform, leadership and strong liquidity. "The second... Read More

Willow Biosciences Inc. (" Willow " or the " Company ") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable ingredients, is pleased to announce that the Board of Directors has appointed Dr. Peter Seufer-Wasserthal as Interim President and Chief Executive Officer, effective July 17, 2022 , in connection with Trevor Peters'... Read More

Willow Biosciences Inc . (" Willow " or the " Company ") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable ingredients along with Inscripta®, a global leader in automated, CRISPR-based gene editing technology, announced today that Willow has incorporated the Onyx Genome Engineering Platform into its strain engineering workflows.... Read More

Willow Biosciences Inc. (" Willow " or the " Company ") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable ingredients is pleased to announce today that is has been engaged by a specialty pharmaceutical company (the " Counterparty ") to optimize an enzyme vital to the development of a large volume Active Pharmaceutical Ingredient... Read More

Willow Biosciences Inc . (" Willow " or the " Company ") (TSX: WLLW) (OTCQB: CANSF) is pleased to announce the voting results from its annual general meeting of shareholders held on May 13, 2022 (the " Meeting "). A total of 42,387,564 common shares, representing approximately 34.31% of the Company's issued and outstanding shares were represented at the meeting. The following nominees were elected as directors of Willow for... Read More

Willow Biosciences Inc. (" Willow " or the " Company ") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of high-value molecules traditionally derived from plants, has released its financial and operating results for the three months ended March 31, 2022 , reporting significant progress to its operational platform and strong liquidity. "The first quarter this... Read More

Willow Biosciences Inc. (" Willow " or the " Company ") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of high-value molecules traditionally derived from plants, announces expanded production capacity with a new manufacturing partnership and progress with respect to its Generally Recognized as Safe (" GRAS ") determination. Expansion of Fermentation... Read More

Willow Biosciences Inc. (" Willow " or the " Company ") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company that develops technology to manufacture pure, consistent and sustainable compounds via yeast biosynthesis, is pleased to announce its financial and operating results for the three months and year ended December 31, 2021 , and filing of its Annual Information Form ("AIF"). Selected financial and operational... Read More

Willow Biosciences Inc. (" Willow " or the " Company ") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company that manufactures pure, consistent and sustainable cannabinoids via yeast biosynthesis, is pleased to announce the results of its in vitro analysis and the first to be reported topical clinical study on... Read More

Willow Biosciences Inc. (" Willow " or the " Company ") (TSX: WLLW) (OTCQB: CANSF) has released its financial and operating results for the three and nine months ended September 30, 2021 , reporting significant advancement in its operations and strong liquidity. "We continued to make significant strides forward in the third... Read More

Willow Biosciences Inc. (" Willow " or the " Company ") (TSX: WLLW) (OTCQX: CANSF), a leading biotechnology company that manufactures ultra-pure, sustainably produced cannabinoids via yeast-based biosynthesis, is pleased to provide the following operational and corporate updates. Commercial Scale Operational Update In March... Read More

illow Biosciences Inc. (TSX: WLLW, OTCQX: CANSF), based in Vancouver, Canada and is a leading biotechnology company that manufactures ultra-pure, sustainably produced cannabinoids via yeast-based biosynthesis, today announced that Trevor Peters, President & Chief Executive Officer, will present live at LifeSciencesInvestorForum.com on September 16 th . DATE: Thursday, September 16 th TIME: 11:00 AM ET LINK:... Read More

Willow Biosciences Inc. (" Willow " or the " Company ") (TSX: WLLW) (OTCQX: CANSF) has released its financial and operating results for the three and six months ended June 30, 2021 , reporting significant advancement in its operations and strong liquidity. "We continued to make substantial strides forward in the second... Read More

Willow Biosciences Inc. (" Willow " or the " Company ") (TSX: WLLW) (OTCQX: CANSF), a leading biotechnology company that manufactures ultra-pure, sustainably produced cannabinoids via yeast-based biosynthesis, is pleased to provide an update on its operations as it transitions to a production company and expands its R&D... Read More

Willow Biosciences Inc. (" Willow " or the " Company ") (TSX: WLLW) (OTCQX: CANSF), a biotechnology company producing ultra-pure, sustainably made compounds, and Cellular Goods PLC (" Cellular Goods ") (LSE: CBX), a U.K. based provider of premium consumer products based on biosynthetically made cannabinoids, are announcing... Read More

Willow Biosciences Inc. (" Willow " or the " Company ") (TSX: WLLW) (OTCQX: CANSF), a Canadian biotechnology company that manufactures ultra-pure, sustainably produced cannabinoids via yeast-based biosynthesis, is pleased to announce that it will be presenting on a panel with other industry leaders at SynBioBeta's "Celebrating... Read More

Willow Biosciences Inc. (" Willow " or the " Company ") (TSX: WLLW) (OTCQX: CANSF), a Canadian biotechnology company that manufactures ultra-pure, sustainably produced cannabinoids via yeast-based biosynthesis, announced today that it has been added to "the Cannabis ETF" (NYSE: THCX) (" THCX "), an exchange traded fund trading... Read More

Willow Biosciences Inc. (" Willow " or the " Company ") (TSX: WLLW) (OTCQX: CANSF) has released its financial and operating results for the three months ended March 31, 2021 , reporting significant advancement in its operations and strong liquidity. "The first quarter represented another significant move forward for us, as we... Read More

Willow Biosciences Inc. (" Willow " or " the Company ") (TSX: WLLW) (OTCQX: CANSF) is pleased to announce the voting results from its annual general and special meeting (the " Meeting ") of shareholders held on April 28, 2021 . A total of 46,817,015 common shares, representing approximately 37.92% of Willow's issued and outstanding shares, were represented at the Meeting. The following nominees were elected as directors of... Read More

Willow Biosciences Inc. (" Willow " or the " Company ") (TSX: WLLW) (OTCQX: CANSF) is pleased to announce that it has completed a series of studies with its development partner, Signum Biosciences, Inc., that demonstrate the safety and anti-inflammatory, anti-aging, and antimicrobial properties of Willow's cannabigerol ("... Read More

Willow Biosciences Inc. (" Willow " or the " Company ") (TSX: WLLW) (OTCQX: CANSF) is pleased to announce that it has completed the first commercial scale fermentation run of its first cannabinoid for market, cannabigerol (" CBG "). "We are very pleased with the yield and quality of our first commercial scale fermentation run... Read More

Willow Biosciences Inc. (" Willow " or the " Company ") (TSX: WLLW) (OTCQX: CANSF) is pleased to announce its financial and operating results for the three months and year ended December 31, 2020 . Selected financial and operational information is outlined below and should be read with Willow's audited consolidated financial statements (the " Financial Statements ") and management's discussion and analysis (the " MD&A ") as... Read More

Willow Biosciences Inc. (" Willow " or the " Company ") (TSX: WLLW) (OTCQX: CANSF) is pleased to provide an update on its previously announced acceleration of the expiry date of 9,320,478 common share purchase warrants (the " 2020 Warrants ") issued on October 29, 2020 (the " Acceleration "). The Company has completed the... Read More

Willow " or the " Company ") (TSX: WLLW) (TSX: WLLW.WT) (OTCQX: CANSF) is pleased to announce that it has closed its previously announced upsized bought deal offering of 17,424,800 common shares (the " Common Shares ") of the Company at a price of $1.65 per Common Share, which includes 2,272,800 Common Shares issued pursuant to the exercise in full of the over-allotment option, for aggregate gross proceeds of approximately... Read More